Enumeral has isolated and sequenced more than 300 anti-PD-1 antibodies from primary B cells. The ... perhaps through an autocrine IL-2 signaling mechanism, ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).. JCO 34 , TPS9599-TPS9599 (2016). DOI: ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

CTLA-4. CTLA-4 and PD-1 can regulate immune responses at different levels and by different mechanisms ().CTLA-4 is expressed on the cell surface of T cells and regulates the amplitude of the early ...

The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

Anti–CTLA-4 (ipilimumab) has not been tested as a single agent for patients with NSCLC, but has some activity in combination with chemotherapy. 2,3 In combination with anti–PD-1/PD-L1, the ...

Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding Provided by PR Newswire Jun 4, 2025, 11:00:00 PM Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM ...